Analysts at Bernstein are out with a report this morning upgrading shares of Biogen Inc. (BIIB) with a ‘Outperform‘ from ‘Market Perform‘ rating. The firm however, lowered its price target for the company to $385 from $436 noting shares have succumbed to a perfect storm of slower earnings growth, reduced guidance and pipeline concerns.
Biogen Inc. shares are currently priced at 20.75x this year’s forecasted earnings.Ticker has a forward P/E of 16.67 and t-12 price-to-sales ratio of 6.86. EPS for the same period is $14.76.
In the past 52 weeks, shares of Cambridge, Massachusetts-based company have traded between a low of $290.85 and a high of $480.18 and are now at $306.30. Shares are down 10.91% year-over-year and 11.61% year-to-date.
Analysts at Morgan Stanley (MS) upgraded their rating on the shares of Qualcomm Incorporated (QCOM). In a research note published on Monday, the firm lifted the name with a ‘Overweight‘ from ‘Equal-Weight‘ rating and set a 12-month base case estimate of from $75 per share.
On valuation measures, Qualcomm Inc. shares are currently priced at 17.07x this year’s forecasted earnings compared to the industry’s 10.65x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.05 and 13.20, respectively. Price/Sales for the same period is 3.65 while EPS is $3.66.
Currently there are 17 analysts that rate QCOM a ‘Buy‘, 13 rate it a ‘Hold‘. 2 analyst rates it a ‘Sell‘. QCOM has a median Wall Street price target of $71.00 with a high target of $85.00.
Teva Pharmaceutical Industries Limited (TEVA) was reiterated a ‘Buy’ by Maxim Group analysts on Monday. The broker also raised its price target on the stock to $74 from $68.
TEVA is up $7.31 at $69.16 on heavy volume. Midway through trading Monday, 27.01 million shares of Teva Pharmaceutical Industries Ltd. ADR have exchanged hands as compared to its average daily volume of 3.50 million shares. The stock has ranged in a price between $66.61-$70.09 after having opened the day at $67.80 as compared to the previous trading day’s close of $61.85.
Over the past year, shares of Petach Tikva, Israel-based company have traded between a low of $47.36 and a high of $70.09. Shares are up 16.44% year-over-year and 8.80% year-to-date.
Expedia Inc. (EXPE) was reiterated as ‘Buy’ with a $130 from $120 price target on Monday by The Benchmark Company. The firm noted that while the pending merger with Orbitz (OWW) and the ongoing DOJ review will remain the focal point for investors, they (the firm’s analysts) think there could be modest upside versus consensus on both the top and bottom line.
EXPE is currently printing a normal average trading volume with the issue trading 732K shares, compared to the average volume of 1.31 million. The stock began trading this morning at $105.51 to currently trade 1.46% lower from the prior days close of $105.70. On an intraday basis it has gotten as low as $104.00 and as high as $105.70.
Expedia shares have declined 3.01% in the last 4 weeks while advancing 7.05% in the past three months. Over the past 5 trading sessions the stock has lost 4.59%.
The Bellevue, Washington-based company, which is currently valued at $13.35 billion, has a median Wall Street price target of $112.50 with a high target of $140.00. Expedia Inc. is up 33.31% year-over-year, compared with a 5.09% gain in the S&P 500.
Comcast Corporation (CMCSA) rating of ‘Outperform’ was reiterated today at RBC Capital Markets with a price target increase of $66 from $65.
CMCSA shares recently lost $0.81 to $61.36. The stock is up 14.66% year-over-year and has gained roughly 8.50% year-to-date. In the past 52 weeks, shares of Philadelphia, Pennsylvania-based company have traded between a low of $49.33 and a high of $64.99.
Comcast Corp. Cl A closed Friday at $62.17. The name has a current market cap of $152.92 billion.